Andres Maldonado's Stock Ratings

HC Wainwright & Co. Analyst

Andres Maldonado is an analyst at HC Wainwright & Co.. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/07/2024

Overall Average Return

-11.8%

Smart Score

42.6%

Overall Average Return Percentile

19th

Number of Ratings

52
Buy NowGet Alert
07/02/2024HOWLBuy Now
Werewolf Therapeutics
$2.18588.07%$15 → $15ReiteratesBuy → BuyGet Alert
06/26/2024HOWLBuy Now
Werewolf Therapeutics
$2.18588.07%$15 → $15ReiteratesBuy → BuyGet Alert
06/25/2024SRRKBuy Now
Scholar Rock Holding
$7.87281.19%$30 → $30ReiteratesBuy → BuyGet Alert
06/20/2024DAWNBuy Now
Day One Biopharmaceutical
$14.80170.27%$40 → $40ReiteratesBuy → BuyGet Alert
06/04/2024SRRKBuy Now
Scholar Rock Holding
$7.87281.19%$30 → $30ReiteratesBuy → BuyGet Alert
06/03/2024HOWLBuy Now
Werewolf Therapeutics
$2.18588.07%$15 → $15ReiteratesBuy → BuyGet Alert
05/29/2024IKNABuy Now
Ikena Oncology
$1.63145.4%$11 → $4MaintainsBuyGet Alert
05/28/2024CGONBuy Now
CG Oncology
$32.09133.72%$75 → $75ReiteratesBuy → BuyGet Alert
05/24/2024HOWLBuy Now
Werewolf Therapeutics
$2.18588.07% → $15ReiteratesBuy → BuyGet Alert
05/23/2024SRRKBuy Now
Scholar Rock Holding
$7.87281.19% → $30ReiteratesBuy → BuyGet Alert
05/20/2024ERASBuy Now
Erasca
$2.35112.77%$8 → $5MaintainsBuyGet Alert
05/10/2024CGONBuy Now
CG Oncology
$32.09133.72% → $75ReiteratesBuy → BuyGet Alert
05/09/2024ERASBuy Now
Erasca
$2.35240.43% → $8ReiteratesBuy → BuyGet Alert
05/08/2024SRRKBuy Now
Scholar Rock Holding
$7.87281.19% → $30ReiteratesBuy → BuyGet Alert
05/07/2024DAWNBuy Now
Day One Biopharmaceutical
$14.80170.27%$50 → $40MaintainsBuyGet Alert
05/06/2024CGONBuy Now
CG Oncology
$32.09133.72% → $75ReiteratesBuy → BuyGet Alert
05/06/2024HOWLBuy Now
Werewolf Therapeutics
$2.18588.07% → $15ReiteratesBuy → BuyGet Alert
04/24/2024DAWNBuy Now
Day One Biopharmaceutical
$14.80237.84% → $50ReiteratesBuy → BuyGet Alert
04/04/2024CGONBuy Now
CG Oncology
$32.09133.72% → $75ReiteratesBuy → BuyGet Alert
03/28/2024ERASBuy Now
Erasca
$2.35240.43% → $8ReiteratesBuy → BuyGet Alert
03/19/2024SRRKBuy Now
Scholar Rock Holding
$7.87281.19% → $30ReiteratesBuy → BuyGet Alert
03/19/2024IKNABuy Now
Ikena Oncology
$1.63574.85% → $11ReiteratesBuy → BuyGet Alert
03/12/2024IKNABuy Now
Ikena Oncology
$1.63574.85%$11 → $11MaintainsBuyGet Alert
03/07/2024HOWLBuy Now
Werewolf Therapeutics
$2.18588.07%$15 → $15MaintainsBuyGet Alert
02/14/2024CGONBuy Now
CG Oncology
$32.09133.72% → $75Initiates → BuyGet Alert
01/19/2024IKNABuy Now
Ikena Oncology
$1.63574.85% → $11ReiteratesBuy → BuyGet Alert
11/28/2023ERASBuy Now
Erasca
$2.35240.43%$10 → $8MaintainsBuyGet Alert
11/15/2023HOWLBuy Now
Werewolf Therapeutics
$2.18588.07% → $15ReiteratesBuy → BuyGet Alert
11/09/2023IKNABuy Now
Ikena Oncology
$1.63574.85%$18 → $11MaintainsBuyGet Alert
10/31/2023HOWLBuy Now
Werewolf Therapeutics
$2.18588.07% → $15ReiteratesBuy → BuyGet Alert
10/12/2023SRRKBuy Now
Scholar Rock Holding
$7.87281.19% → $30ReiteratesBuy → BuyGet Alert
10/11/2023ERASBuy Now
Erasca
$2.35325.53% → $10Initiates → BuyGet Alert
09/19/2023HOWLBuy Now
Werewolf Therapeutics
$2.18588.07% → $15ReiteratesBuy → BuyGet Alert
09/15/2023HOWLBuy Now
Werewolf Therapeutics
$2.18588.07% → $15ReiteratesBuy → BuyGet Alert
08/10/2023IKNABuy Now
Ikena Oncology
$1.631004.29% → $18ReiteratesBuy → BuyGet Alert
08/10/2023HOWLBuy Now
Werewolf Therapeutics
$2.18588.07% → $15ReiteratesBuy → BuyGet Alert
08/10/2023SRRKBuy Now
Scholar Rock Holding
$7.87281.19% → $30ReiteratesBuy → BuyGet Alert
08/08/2023DAWNBuy Now
Day One Biopharmaceutical
$14.80237.84% → $50ReiteratesBuy → BuyGet Alert
08/07/2023IKNABuy Now
Ikena Oncology
$1.631004.29% → $18ReiteratesBuy → BuyGet Alert
07/13/2023SRRKBuy Now
Scholar Rock Holding
$7.87281.19% → $30ReiteratesBuy → BuyGet Alert
06/05/2023DAWNBuy Now
Day One Biopharmaceutical
$14.80237.84%$45 → $50MaintainsBuyGet Alert
05/24/2023IKNABuy Now
Ikena Oncology
$1.631004.29% → $18ReiteratesBuy → BuyGet Alert
05/18/2023DAWNBuy Now
Day One Biopharmaceutical
$14.80204.05% → $45ReiteratesBuy → BuyGet Alert
05/11/2023HOWLBuy Now
Werewolf Therapeutics
$2.18588.07% → $15ReiteratesBuy → BuyGet Alert
05/04/2023IKNABuy Now
Ikena Oncology
$1.631004.29% → $18Assumes → BuyGet Alert
03/23/2023HOWLBuy Now
Werewolf Therapeutics
$2.18588.07%$20 → $15Reiterates → BuyGet Alert
03/08/2023SRRKBuy Now
Scholar Rock Holding
$7.87281.19% → $30Reiterates → BuyGet Alert
03/07/2023DAWNBuy Now
Day One Biopharmaceutical
$14.80204.05% → $45Reiterates → BuyGet Alert
01/09/2023DAWNBuy Now
Day One Biopharmaceutical
$14.80204.05%$35 → $45MaintainsBuyGet Alert
12/15/2022DAWNBuy Now
Day One Biopharmaceutical
$14.80136.49% → $35Initiates → BuyGet Alert
09/19/2022SRRKBuy Now
Scholar Rock Holding
$7.87281.19% → $30Assumes → BuyGet Alert
06/02/2022HOWLBuy Now
Werewolf Therapeutics
$2.18817.43% → $20Assumes → BuyGet Alert

Recent Analyst Stock Rating News

A Closer Look at 9 Analyst Recommendations For CG Oncology
Where Werewolf Therapeutics Stands With Analysts
Critical Insights From Werewolf Therapeutics Analyst Ratings: What You Need To Know
Decoding 10 Analyst Evaluations For CG Oncology
The Analyst Verdict: Werewolf Therapeutics In The Eyes Of 4 Experts
The Analyst Landscape: 4 Takes On Ikena Oncology
Fulcrum Therapeutics To Rally Around 120%? FDA Update Removes Overhang On Pivotal Program
Tuesday, the FDA lifted the clinical hold on Fulcrum Therapeutics Inc's (NASDAQ: FULC) Investigational New Drug (IND) application for FTX-6058 for the potential treatment of 
Ikena Oncology Acquires Pionyr Immunotherapeutics: Analysts See The Deal As Positive Move
Ikena Oncology Inc (NASDAQ: IKNA) acquired Pionyr Immunotherapeutics Inc, a privately-held biotechnology company, in 
Vertex Pharma Raises Annual Forecast On Strong Uptake For Cystic Fibrosis Drug, Analysts Says Investors' Focus On Non-CF Pipeline
Vertex Pharmaceuticals Inc's (NASDAQ: VRTX) Q2 sales increased 14% to $2.49 billion, beating the consensus of $2.41 bill
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free